Recent reports have shown that polymorphisms in the TRPS1 and TRIB1 genes are associated with plasma lipid levels and the risk of cardiovascular disease. This study evaluates the associations of TRPS1 and TRIB1 polymorphisms with subclinical atherosclerosis (SA) and plasma lipid levels in Mexican individuals. This study included 1406 Mexican mestizo individuals (417 individuals with SA and 989 healthy controls). Genotyping of TRPS1 and TRIB1 polymorphisms was performed using TaqMan assays in a real-time PCR system. To analyze whether these polymorphisms are associated with SA and plasma lipid levels, we used logistic regression (OR 95% CI), adjusted for confounding factors. The AA genotype of the TRPS1 rs2737229 A/C polymorphism showed a significant association with the risk of developing SA under multiple genetic models codominant: OR = 1.61 (95% CI: 1.10–2.36), p = 0.048; recessive: OR = 1.42 (1.02–1.99), p = 0.039; additive: OR = 1.26 (1.05–1.53), p = 0.015. Similarly, the TT genotype of the TRIB1 rs2954029 T/A polymorphism was also significantly associated with the risk of developing SA codominant: OR = 1.63 (1.10–2.43), p = 0.033; recessive: OR = 1.64 (1.13–2.37), p = 0.009. In a sub-analysis of SA individuals, individuals with homozygous AA for the TRPS1 rs2737229 polymorphism had higher LDL cholesterol levels 135 mg/dL (110–148) than those with homozygous CC 118 mg/dL (99–139) (p < 0.003). The analysis of the TRIB1 rs2954029 polymorphism showed that carriers of the TT genotype had increased glucose levels 97 mg/dL (87–118) compared to carriers of the AA genotype 91 mg/dL (84–99) (p < 0.002). In summary, our findings showed that, in Mexican Mestizos, the AA genotype of the TRPS1 rs2737229 A/C SNP and the TT genotype of the TRIB1 rs2954029 A/T polymorphism are associated with a higher risk of developing SA and elevated levels of glucose and LDL cholesterol.
Vargas-Alarcón et al. (Sun,) studied this question.